Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7415947 | 0.87 | NR1H2 (0.50) | NR1H2USP2SMN1; SMN2ESR2CTSK | |
| SCHEMBL13048672 | 0.77 | ESR2 (0.46) | NR1H2USP2SMN1; SMN2ESR2ADORA1 | |
| SCHEMBL12435353 | 0.77 | NR1H2 (0.44) | NR1H2USP2SMN1; SMN2ESR2ADORA1 | |
| SCHEMBL22056024 | 0.77 | NR1H2 (0.38) | NR1H2USP2SMN1; SMN2ESR2CTSK | |
| SCHEMBL626936 | 0.76 | ESR2 (0.49) | NR1H2USP2SMN1; SMN2ESR2CTSK | |
| SCHEMBL25539482 | 0.73 | ADORA1 (0.42) | NR1H2USP2SMN1; SMN2ESR2ADORA1 | |
| SCHEMBL2292608 | 0.72 | USP2 (0.52) | NR1H2USP2SMN1; SMN2ESR2GPR119 | |
| SCHEMBL344121 | 0.71 | USP2 (0.41) | NR1H2USP2SMN1; SMN2ESR2CTSK | |
| SCHEMBL18975935 | 0.71 | USP2 (0.41) | NR1H2USP2SMN1; SMN2ESR2CTSK | |
| SCHEMBL22056057 | 0.71 | NR1H2 (0.40) | NR1H2USP2SMN1; SMN2ESR2ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023224963-A1 | DUAL-ACTING ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONISTS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023224963-A1 | DUAL-ACTING ANGIOTENSIN AND ENDOTHELIN RECEPTOR ANTAGONISTS | ARIA PHARMACEUTICALS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| CN-108698992-B | 2-cyanoisoindoline derivatives for the treatment of cancer | 特殊治疗有限公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3429994-B1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LTD (GB) | 2021-06-16 | — | — | EP | disclosed |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-16 | — | — | US | disclosed |
| EP-3429994-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | Mission Therapeutics Limited (GB) | 2019-01-23 | — | — | EP | disclosed |
| US-20190010122-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2019-01-10 | — | — | US | disclosed |
| CN-108698992-A | 2- cyano isoindoline derivatives for treating cancer | 特殊治疗有限公司 | 2018-10-23 | — | — | CN | disclosed |
| WO-2017158388-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2017-09-21 | — | — | WO | disclosed |
| US-20110257208-A1 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-20110257208-A1 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. | 2011-10-20 | — | — | US | disclosed |
| US-20110257208-A1 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. | 2011-10-20 | — | — | US | disclosed |
| EP-2364316-A1 | 6, 7 -dihydro- 5h- pyrrolo [3, 4-d¨pyrimidin-4-yl]-quinolin-3 -ylamine compounds useful as FAAH modulators and uses thereof | Renovis, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010059610-A1 | 6, 7 -DIHYDRO- 5H- PYRROLO [3, 4-D] PYRIMIDIN-4-YL] -QUINOLIN-3 -YLAMINE COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059610-A1 | 6, 7 -DIHYDRO- 5H- PYRROLO [3, 4-D] PYRIMIDIN-4-YL] -QUINOLIN-3 -YLAMINE COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257208-A1 | COMPOUNDS USEFUL AS FAAH MODULATORS AND USES THEREOF | FAAH, FAAH2, CNR2 | NR1H2 400/4885USP2 1479/4885SMN1; SMN2 1690/4885 |
| US-20190010122-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | USP7, USP47, USP2 | NR1H2 2297/4885USP2 3/4885SMN1; SMN2 4184/4885 |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | USP7, USP47, USP2 | NR1H2 2297/4885USP2 3/4885SMN1; SMN2 4184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.